Celgene Corporation (CELG) Given Consensus Rating of “Buy” by Analysts
Shares of Celgene Corporation (NASDAQ:CELG) have been assigned an average rating of “Buy” from the thirty analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, twenty-two have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $147.39.
CELG has been the subject of a number of research analyst reports. Jefferies Group LLC set a $154.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Saturday, May 13th. Vetr downgraded shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $132.90 price objective for the company. in a research note on Thursday, May 11th. BTIG Research reaffirmed a “buy” rating and set a $138.00 price objective on shares of Celgene Corporation in a research note on Monday, May 1st. Cantor Fitzgerald set a $159.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, April 27th. Finally, Cann reaffirmed a “buy” rating on shares of Celgene Corporation in a research note on Thursday, April 27th.
In other news, insider Rupert Vessey sold 4,785 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gilla Kaplan sold 7,500 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 253,761 shares of company stock valued at $33,792,445. Company insiders own 0.95% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Thompson Davis & CO. Inc. raised its stake in Celgene Corporation by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares in the last quarter. Motco raised its stake in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Celgene Corporation during the first quarter valued at about $118,000. Carroll Financial Associates Inc. raised its stake in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares in the last quarter. Finally, Balentine LLC raised its stake in Celgene Corporation by 83.5% in the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 481 shares in the last quarter. Institutional investors own 78.34% of the company’s stock.
Shares of Celgene Corporation (NASDAQ:CELG) traded down 1.20% on Tuesday, reaching $131.37. 2,446,018 shares of the company’s stock traded hands. The stock’s 50-day moving average price is $134.10 and its 200-day moving average price is $124.62. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00. The stock has a market capitalization of $102.78 billion, a price-to-earnings ratio of 40.68 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the prior year, the company posted $1.44 EPS. The company’s quarterly revenue was up 18.7% compared to the same quarter last year. Equities analysts predict that Celgene Corporation will post $7.32 EPS for the current year.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.